Merck and Moderna’s personalized mRNA neoantigen vaccine, intismeran autogene, met primary and secondary endpoints in its Phase III trial for high-risk melanoma, marking the first late-stage success for this modality.CNBCFierce BiotechTradingKeyThe News International
The combination with Keytruda significantly improved recurrence-free survival in over 1,100 patients, validating the commercial potential of individualized cancer vaccines beyond mRNA's initial pandemic applications.Fierce BiotechCNBCGuruFocus
An experimental personalized cancer vaccine from Merck and Moderna showed positive initial results in its first-ever late-stage trial, the companies announced Wednesday, bringing them one step closer to filing for approval of the treatment option. The mRNA-based shot in combinati…
Merck, Moderna’s personalized cancer vaccine slows recurrence in phase 3, setting up approval push Fierce Biotech
Moderna and Merck announced positive Phase 3 results for their jointly developed personalized mRNA cancer vaccine in high-risk melanoma patients, marking a historic milestone for mRNA technology in oncology. Combining the vaccine with Keytruda significantly delayed cancer recurre…
According to the National Cancer Institute, in 2023 more than 1.5 million people in the US suffered from melanoma Merck and Moderna’s experimental personalized cancer vaccine has shown promising success in Melanoma’s first-ever late-stage trial. The landmark success in the trial …
A Phase III trial of intismeran autogene, the mRNA-based individualized neoantigen therapy co-developed by Merck (NYSE: MRK) and Moderna (Nasdaq: MRNA), has met both its primary and a key secondary endpoint in patients with completely resected stage IIB-IV melanoma, the companies…
Merck and Moderna’s experimental personalized cancer vaccine has delivered positive results in its first phase three trial, the companies announced Wednesday, moving the treatment closer to potential regulatory approval The mRNA vaccine, combined with Merck’s Keytruda, met the ma…
Moderna's personalized cancer vaccine shows success in Phase 3 trial The Business Journals
Moderna is headquartered at 325 Binney Street in Cambridge. Moderna Inc.’s personalized cancer vaccine is now one big step closer to seeking approval. Merck and Moderna said that new Phase 3 data showed intismeran autogene combined with Keytruda reduced melanoma recurrence and sp…
Moderna and Merck's jointly developed personalized mRNA cancer vaccine has succeeded in suppressing cancer recurrence and metastasis in high-risk melanoma patients in a late-stage clinical trial. This marks the first time a personalized mRNA cancer therapeutic has met its primary…
Merck and Moderna announced positive initial results from their first late-stage trial of an experimental personalized cancer vaccine combined with Merck's immunotherapy Keytruda. The phase three trial involving over 1,100 melanoma patients showed the combo significantly extended…
Positive Results for Personalized Cancer Vaccine from MRK and MR GuruFocus
NTx Bio Powers Baylor College of Medicine's Manufacturing of a Personalized Cancer Vaccine in Diakonos Oncology's Phase 1 Refractory Melanoma Trial Business Wire
[RECRUITING · PHASE2 · Geneos Therapeutics] This is a randomized, open-label, multi-site Phase II study of a personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in subjects with histologically or cytologically confirmed diagnosis of HCC based on p…
Researching how Individualized Neoantigen Therapies may help a patient's immune system target their cancer in a personalized way WKOW